Turku, Finland

Eeva-Liisa Savola


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovations of Eeva-Liisa Savola in Drug Development**

Introduction

Eeva-Liisa Savola is an accomplished inventor located in Turku, Finland. With a focus on pharmaceutical innovations, she has made significant contributions to the field of medical treatments. Her notable patent, which addresses diseases mediated by the alpha-2B-adrenoceptor, showcases her expertise and dedication to improving health outcomes.

Latest Patents

Eeva-Liisa Savola holds one patent titled "Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor." This patent presents a method for treating or preventing conditions in mammals that are mediated through the alpha-2B-adrenoceptor. The method involves administering an effective amount of a selective alpha-2B-adrenoceptor antagonist, with specific compounds identified in her patent documentation.

Career Highlights

Eeva-Liisa currently works at Oy Juvantia Pharma Ltd., where she contributes to research and development efforts aimed at innovative drug solutions. Her focus on targeting alpha-2B-adrenoceptors highlights her commitment to advancing therapeutic options for various diseases.

Collaborations

In her professional journey, Eeva-Liisa has collaborated with notable colleagues, including Siegfried Wurster and Mia Engström. These collaborations enhance the research and development processes at Juvantia Pharma, allowing for the exchange of ideas and expertise in the pharmaceutical industry.

Conclusion

Eeva-Liisa Savola exemplifies the impact of dedicated inventors in the field of pharmaceuticals. Her patent on the treatment of diseases mediated by alpha-2B-adrenoceptors is a testament to her innovative spirit and commitment to advancing medical science. As she continues her work at Oy Juvantia Pharma Ltd., her contributions are poised to influence the future of drug development significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…